echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In the 5G era, the development of pharmaceutical companies presses the "fast forward button"!

    In the 5G era, the development of pharmaceutical companies presses the "fast forward button"!

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    【Pharmaceutical Network Industry News】In the ointment production workshop of Ma Yinglong, a traditional Chinese medicine enterprise, through the application of 5G technology, almost all production processes such as filling and packaging are covered by automation equipment, and the whole work is orderly, and the production line process can be remotely monitored and tracked in real time, which not only improves work efficiency, but also greatly reduces labor costs; In the digital workshop of the fifth phase of GMP base of Huason Pharmaceutical, with the help of 5G, artificial intelligence, Internet of Things and cloud computing technologies, the workshop has realized the digital management of the whole process of drug production, and "the whole Chinese medicine extraction workshop saves about 80 people compared with the traditional pharmaceutical workshop when it rotates in 3 shifts", achieving the purpose of lean production, cost reduction and efficiency increase.
    .
    .
    In the 5G era, the development of pharmaceutical companies is pressing the "fast forward button"
    .
    In the 5G era, the development of pharmaceutical companies presses the "fast forward button"! (Image source: Pharma Network) Behind the active embrace of 5G by pharmaceutical companies, it is inseparable from the strong support
    given by the policy side to the "5G + industrial Internet" pharmaceutical manufacturing industry.
    In November 2021, the newly released "5G + Industrial Internet" Pharmaceutical Manufacturing Industry Application Guide provides a standard
    for the 5G intelligent transformation of the national pharmaceutical manufacturing industry.
    According to the "Guidelines", pharmaceutical companies can use 5G technology
    from pharmaceutical, research and development, storage and transportation.
    In the pharmaceutical sector: use the 5G platform to monitor the preparation status of raw materials in real time, capture and aggregate electronic experimental records, instrument records, medical samples, biological activities and other data; In the research and development process, 5G + machine vision + robot is used to realize unmanned control of pharmaceutical dispensing and improve production efficiency; In addition, in the storage and transportation process, 5G wireless technology is used to connect AGVs, aseptic robots, articulated robots, reactors and other equipment to build online management systems
    such as raw and auxiliary material feeding, automatic monitoring of drug quality, and automatic warehousing of finished products.
    In addition, due to the special properties of drugs, the guidelines propose "paperless office" and "unmanned operation", that is, the use of 5G drones, intelligent robots and other technologies to realize automation and intelligent scheduling in pharmaceutical circulation, reduce the intervention of personnel in drugs, and solve the risk
    of cross-contamination caused by manual operations through unmanned operation and remote control system.
    In the past, the manufacturing process of pharmaceutical enterprises in China was mainly based on manual operation, the level of digitalization was low, the management system was not perfect enough, the labor cost was high, and the product quality was difficult to be well guaranteed
    .
    With high bandwidth, low latency, reliability and support for massive connections, 5G + Industrial Internet can help solve the problems in the traditional pharmaceutical manufacturing process, help the digital transformation of the pharmaceutical industry, promote the modernization of the industrial chain, and promote the high-quality innovation and development of
    pharmaceutical manufacturing.
    According to industry statistics, as of the end of June 2022, the number of pharmaceutical manufacturing enterprises in China was 8,688, an increase of 351 over the end of the previous year
    .
    At present, many pharmaceutical companies, including Ma Yinglong and Huason Pharmaceutical, have embraced 5G, and most of them have said that after the "5G+" functional scenario, the production and operation efficiency has been significantly improved
    .
    The industry believes that with the in-depth promotion of "5G + industrial Internet", the traditional pharmaceutical manufacturing industry will be reshaped, and digital empowerment will bring a larger market
    .
    In fact, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry" jointly issued by the Ministry of Industry and Information Technology and other eight departments also proposed to accelerate product innovation and industrialization technology breakthroughs, enhance the stability and competitiveness of the industrial chain, enhance supply security capabilities, promote the upgrading of pharmaceutical manufacturing capacity systems, and create new advantages
    in international competition.
    It can be seen that the innovation and transformation of pharmaceutical enterprises has become a trend, and digitalization will become an important topic
    in the process of enterprise transformation.
    According to the Industrial Internet Innovation and Development Action Plan (2021-2023), the next few years will be the introduction period
    of 5G technology.
    The industry expects that not only traditional pharmaceutical companies will accelerate their digital transformation, but also their upstream pharmaceutical equipment will develop in the direction of digitalization and informatization, and the leading enterprises with advanced layout are expected to embrace a new round of opportunities
    .
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
    to anyone.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.